The combination of OncoVista’s extensive in-house pre-clinical and clinical expertise with our global drug development network will lead to rapid and cost-effective regulatory approval and commercialization of novel therapies for the treatment of cancer.

The product portfolio includes:

• a Phase II drug for treatment of solid tumors (OVI-237)
• a Phase I/II drug for treatment of leukemia (OVI-123)
• a compound in pre-clinical development directed to IND filing (OVI-117)
• compounds at the discovery phase

The Company will realize revenues through licensing/milestone fees and royalties flowing from out-licensing/partner agreement.
 
OncoVista will market and commercialize our drugs through strategic partnerships with leaders in the oncology market.